Clinical evaluation of octreotide combined with esomeprazole in treating peptic ulcer bleeding
HU Yu
MIAO Zhengrun
ZHANG Siyu
Abstract：Objective To analyze the efficacy of octreotide combined with esomeprazole in the treatment of pep-tic ulcer bleeding(PUB),and to compare the changes in the levels of serum neutrophil-to-lymphocyte ratio(NLR)and plate-let-to-lymphocyte ratio(PLR).Methods A prospective controlled study design was used.A total of 105 patients with PUB ad-mitted to Huainan Oriental Hospital Group General Hospital from January 2022 to January 2025 were included and divided into the control group(n=52,treated with esomeprazole)and the combined group(n=53,treated with esomeprazole plus octreotide)according to simple random sampling.The clinical efficacy between the two groups was compared,as well as the levels of serum NLR,PLR,and interleukins(IL)2,IL-6,IL-17 before and after treatment,the four coagulation indicators,and adverse reactions.Results The total effective rate of the combined group was significantly higher than that of the control group(96.23%(51/52)vs 82.69%(43/52))(χ2=5.126,P<0.05).The hospitalization time and hemostasis time of the combined group were both shorter than those of the control group((5.40±1.17)d,(23.46±3.33)h vs(7.59±2.28)d,(32.13±5.08)h)(t=6.209,10.362,both P<0.05),and the blood transfusion volume of the combined group was lower than that of the control group((284±56)mL vs(418±62)mL)(t=11.627,P<0.05).The prothrombin time,activated partial thromboplastin time and thrombin time in the combined group were shorter than those in the control group((9.40±1.17)s,(22.59±2.73)s,(12.76±1.65)s vs(11.61±1.68)s,(27.53±2.86)s,(15.73±2.78)s)(t=7.834,9.055,6.672,all P<0.05),and the level of fibrinogen in the combined group was higher than that in the control group((2.81±0.38)g/L vs(2.12±0.27)g/L)(t=10.742,P<0.05).The IL-2 level in the combined group was higher than that in the control group((3.70±0.71)ng/mL vs(2.81±0.66)ng/mL)(t=6.650,P<0.05),while the levels of PLR,NLR,IL-6 and IL-17 in the combined group were lower than those in the control group((5.40±0.72),(22.63±3.68),(33.29±3.63),(169.36±17.65)pg/mL vs(6.37±0.84),(26.37±4.28),(37.83±3.86),(182.27±20.78)pg/mL)(t=4.804,6.357,6.210,3.433,all P<0.05).The incidence of adverse reactions was 1.89%(1/53)in the combination group and 9.62%(5/52)in the control group,and the difference was not statistically significant(χ2=2.748,P=0.097).Conclusion Octreotide combined with esomeprazole has a significant effect in the treatment of PUB,and can improve coagulation function,regulate NLR and PLR levels,reduce inflamma-tory responses,without increasing the risk of adverse events.
Keywords：octreotideesomeprazolepeptic ulcerupper gastrointestinal bleedingefficacyneutrophil-to-lymphocyte ratioplatelet-to-lymphocyte ratio
Publication Date：2026-02-25
Online Publishing Date：2026-03-16(First online date of this platform, not the publication date of the document)
Pages：4( 212-215 )